ALNY
ALNY
Alnylam Pharmaceuticals, Inc.
$293.17
+$1.69 (+0.58%)
Mkt Cap: $39.14B
Home / ALNY / Financial Statements

Alnylam Pharmaceuticals, Inc. (ALNY) Financial Statements

Export as clean Markdown. Drag & drop into ChatGPT, Claude, or Gemini.

Metric TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue
$4.29B
$3.71B ↑65.2%
$2.25B ↑23.0%
$1.83B ↑76.2%
$1.04B ↑22.9%
$844.29M
Cost of Revenue
$819.03M
$677.17M ↑109.4%
$323.37M ↑4.2%
$310.41M ↑83.9%
$168.82M ↑20.5%
$140.14M
Gross Profit
$3.47B
$3.04B ↑57.8%
$1.92B ↑26.8%
$1.52B ↑74.8%
$868.60M ↑23.4%
$704.14M
R&D Expenses
$1.42B
$1.32B ↑17.6%
$1.13B ↑12.1%
$1.00B ↑13.7%
$883.01M ↑11.5%
$792.16M
SG&A Expenses
$1.29B
$1.21B ↑24.1%
$975.53M ↑22.6%
$795.65M ↑3.2%
$770.66M ↑24.2%
$620.64M
Operating Income
$752.14M
$501.58M ↑383.6%
-$176.88M ↑37.3%
-$282.18M ↑64.1%
-$785.07M ↓10.8%
-$708.65M
Interest Expense
$283.27M
$252.63M ↑78.1%
$141.86M ↑17.0%
$121.22M ↓22.3%
$155.97M ↑9.1%
$143.02M
Income Tax
-$22.14M
$9.40M ↑109.5%
-$99.22M
$6.72M ↑61.5%
$4.16M ↑512.2%
$680,000.00
Net Income
$577.22M
$313.75M ↑212.8%
-$278.16M ↑36.8%
-$440.24M ↑61.1%
-$1.13B ↓32.6%
-$852.82M
EBITDA
$613.59M
$557.24M ↑411.6%
-$178.85M ↑30.7%
-$258.24M ↑72.1%
-$926.56M ↓40.1%
-$661.56M
EPS
4.21
2.33 ↑206.9%
-2.18 ↑38.1%
-3.52 ↑62.2%
-9.30 ↓29.2%
-7.20
Shares Out (Diluted)
541.53M
134.68M ↑5.5%
127.65M ↑2.2%
124.91M ↑2.6%
121.69M ↑2.7%
118.45M